Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06297603 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | PHASE3 | ACTIVE NOT_RECRUITING | 320 | — | — | Mar 15, 2024 | Nov 1, 2026 | Dec 24, 2025 | 76 | United States, Argentina +5 |
| NCT05929079 | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | PHASE3 | ACTIVE NOT_RECRUITING | 1,000 | — | — | Jul 11, 2023 | May 1, 2026 | Apr 13, 2026 | 98 | United States, Argentina +6 |
| Arm | Type | Description |
|---|---|---|
| Retatrutide Dose 1 | EXPERIMENTAL | Participants will receive retatrutide administered subcutaneously (SC). |
| Retatrutide Dose 2 | EXPERIMENTAL | Participants will receive retatrutide administered SC. |
| Retatrutide Dose 3 | EXPERIMENTAL | Participants will receive retatrutide administered SC. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| Retatrutide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have Type 2 Diabetes (T2D) * Have HbA1c ≥7.0% (53 millimoles per mole (mmol/mol)) to ≤10.5% (91 mmol/mol) * Have moderate or severe renal impairment * Have been on the following stable diabetes treatment during 90 days prior to screening * basal insulin (≥20 International U...